Purdue Pharma hires proven deal maker as SVP licensing and business development
STAMFORD, Conn. — Purdue Pharma on Monday announced that Alan Butcher has joined the company as SVP licensing and business development. Butcher will have responsibility for all of Purdue's efforts to acquire or in-license commercial, near-commercial, and development-stage products that would benefit from the company's patient-focused commercial capabilities.
"We're bringing aboard a proven leader," said Purdue president and CEO Mark Timney. "Alan brings valuable new skills and experience to Purdue at a time when business development is a core strategic focus for our firm."
Butcher is an experienced pharmaceutical executive, with multiple high-value deals completed throughout his career. Since 2012, he has been VP business development at Shire Pharmaceuticals. Butcher completed Shire's first ophthalmic product acquisition through the purchase of SARcode Bioscience and he supported, or led, several other transactions including the acquisition of NPS.
Prior to joining Shire, Butcher was VP and general manager of implant drug delivery for Endo Pharmaceuticals. In that role, he was responsible for developing business strategy, P&L management and the development of product candidates and alternative technologies. He joined Endo as VP business and corporate development in 2007, with responsibility for corporate development, as well as acquisition strategy, analysis and execution.
From 2002 to 2007, Butcher was director of worldwide business development transactions at GlaxoSmithKline, where he managed the valuation, negotiation and execution of intellectual property and product licensing deals. He had entered the business development function at Bristol-Myers Squibb in 2000 after holding several positions as a research scientist.
Butcher holds a Bachelor's of Science in Clinical Microbiology and a Master's of Science in Biology with a concentration in Molecular Biology and Genetics from West Chester University of Pennsylvania. He also is a graduate of Cornell University's Johnson Graduate School of Management.
Diplomat Pharmacy boosts data security with new chief information security officer appointment
FLINT, Mich. – Diplomat Pharmacy on Thursday announced the addition of Shannon Beltrand to their senior leadership team as chief information security officer. In this role, Beltrand will be responsible for securing and properly monitoring Diplomat's data, systems and facilities to ensure that Diplomat is secure both internally and externally. Additionally, she will play key roles in systems auditing and business continuity planning.
"We are very excited to have someone of Shannon's caliber and experience joining the Diplomat team," stated Jeffrey Rowe, director and EVP operations at Diplomat. "Her expertise in cyber security will allow Diplomat's patients and partners to have confidence that our systems and data are governed for state-of-the-art protection."
Beltrand brings over 20 years of experience in information technology with several years experience in security of information systems and overall security management. Most recently, Beltrand worked as the director of information security and service management at Data Recognition Corporation, leading the company's enterprise information security program and IT service management processes. Prior to that role, Beltrand served as the company's director of software development, director of information services, manager of information services and project manager of information services.
In addition to her extensive experience in technology and data, Beltrand holds a Bachelor of Arts in American Studies from Pine Manor College in Chestnut Hill, Mass., and a master's degree in organizational leadership and technology from St. Catherine University in St. Paul, Minn.
GPhA establishes new division in Biosimilars Council
WASHINGTON — The Generic Pharmaceutical Association announced Thursday the launch of the Biosimilars Council, a division of GPhA.
“Following unanimous Board of Directors’ approval, the Biosimilars Council is the culmination of the Association’s longstanding and unwavering commitment to patient access to safe, affordable and lifesaving biosimilar medicines," stated Craig Wheeler, GPhA board chairman and president and CEO of Momenta Pharmaceuticals. "The GPhA Biosimilars Council is designed to meet the unique needs of healthcare companies as they navigate this emerging space,” he said.
“In addition to being a voice with policymakers, this new division will be an invaluable partner for patients, providers, manufacturers, consumer groups and stakeholders from all corners of the supply chain seeking to stay apprised of critical developments regarding biosimilars,” Wheeler said. “The GPhA Biosimilars Council also will be a key resource for organizations seeking relationship building opportunities, and a forum for indepth scientific, regulatory, legislative and policy discussions.”
The Biosimilars Council will comprise manufacturers and stakeholders working to ensure a positive regulatory, reimbursement, political and policy environment that supports patient access to these more affordable new medicines. The Biosimilars Council also is the industry’s first educational resource for the general public and patient groups seeking information about the safety and effectiveness of biosimilars.
Among the first offerings of the Biosimilars Council is a new educational handbook, "The Next Frontier for Improved Access to Medicines: Biosimilars and Interchangeable Biologic Products." This publication explains the benefits and science behind biosimilar medicines — safe, effective alternatives to costly biologic therapies. It explains who will benefit from access to these medicines, outlines the legal and regulatory framework, and illuminates the quality manufacturing and development process in approachable language.
The GPhA Biosimilars Council will begin operations immediately. As per recently adopted changes to the GPhA bylaws, a Biosimilar board, elected by members of the Biosimilars Council, will develop the Association’s biosimilar activities and programming consistent with the longstanding mission of GPhA and the association’s board of directors. With a roster of committed members and full startup funding, the new division will supplement GPhA’s regulatory, government affairs, policy and communications/education team to support anticipated activities. The GPhA Biosimilars Council will welcome all biosimilar companies dedicated to bringing more affordable biosimilar medicines to US patients as it works to continue its leadership in supporting this emerging industry.
“GPhA and its members historically have been the industry pioneers on biosimilars, beginning with their role as the fundamental organizing force behind the law which created the biosimilar pathway. The Biosimilars Council is the next evolution in this leadership, and will ensure these new medicines will deliver tremendous benefits for both our health and our healthcare system,” said GPhA president and CEO Ralph Neas. “We look forward to continuing to work with our strategic partners and all stakeholders who share our vision of the transformative potential of biosimilars and interchangeable biologics.”
Loading Post Please Wait...